P/VPA
1,5
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
$1.8B
Market Cap • 02/09/2026
2023
(há 3 anos)
Fundação
2023
(há 3 anos)
IPO
NASDAQ
Listagem
Estados Unidos
País
Valuation
P/R
—
P/EBITDA
—
P/FCO
—
P/FCL
—
P/L
—
VPA
17,6
LPA
—
Market Cap
Valor de Mercado
1,8B
Valor da Firma (EV)
856,5M
EV/Receita
0
EV/EBITDA
-2,6
EV/EBIT
-2,6
Proventos
Dividendo por Ação
0
Dividend Yield
0%
Buyback Yield
-44,7%
Total Yield
-44,7%
Payout
0%
Lucros/Prejuízos Acumulados
-721,7M
Lucratividade
Margem Bruta
—
Margem EBITDA
—
Margem EBIT
—
Margem Líquida
—
D&A/EBITDA
0%
P&D/Receita
0%
Capex/Receita
0%
Capex/D&A
3,4%
Capex/FCO
0%
SBC/FCO
—
% Imobilizado
0,9%
% Goodwill
0%
ROE
—
ROIC
—
Alavancagem
Dív. Líq./EBITDA
3
Dívida/Patrimônio Líq.
0%
Liquidez Corrente
26,4
Quick Ratio
25,9
Índice de Cobertura de Juros
—
Premium
- Acesso completo sem restrições
- Histórico de dados ilimitado
- Vídeos de análises
- Destaques trimestrais
- Tabela customizável
- Ranking
- Discussões
...e muito mais!